Bass strikes again, targets anaesthetic drug in IPR

02-12-2015

Bass strikes again, targets anaesthetic drug in IPR

Dima Sobko / Shutterstock.com

Hedge fund manager Kyle Bass has filed another inter partes review (IPR), teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.


Diprivan, Patent Trial and Appeal Board, USPTO, Kyle Bass, Coalition for Affordable Drugs, Fresenius Kabi, IPR, Inter Partes Review

More on this story

Kyle Bass targets Alpex speckled tablet patent
25-11-2015

LSIPR